Qingdao Vland Biotech INC. (SHA:603739)

Market Cap	3.78B +15.6%
Revenue (ttm)	1.39B +10.0%
Net Income	83.57M +26.2%
EPS	0.33 +27.7%
Shares Out	253.03M
PE Ratio	45.05
Forward PE	n/a
Dividend	0.10 (0.68%)
Ex-Dividend Date	May 30, 2025

Volume	5,416,594
Average Volume	6,953,471
Open	14.54
Previous Close	14.75
Day's Range	14.51 - 15.08
52-Week Range	12.23 - 18.41
Beta	0.52
RSI	47.92
Earnings Date	Apr 25, 2026

About SHA:603739

Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated, and poultry and swine vaccines, as well as egg yolk antibodies; poultry drugs comprising anti-parastic, antivir...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 1,535
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603739

Financial Performance

In 2024, SHA:603739's revenue was 1.32 billion, an increase of 10.16% compared to the previous year's 1.20 billion. Earnings were 62.64 million, a decrease of -22.39%.